JPRN-UMIN000015935已完成未知
Exploratory trial for confirmation of safety on the mask with the ingredient of cinnamon bark extraction - Trial for confirmation of saefty on the mask with the ingredient of cinnamon bark extraction
Department of Japanese-Oriental (Kampo) Medicine,Graduate School of Medicine, Chiba University0 个研究点目标入组 50 人开始时间: 2015年1月12日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
Four out of 49 subjects withdrew. Side effects e.g. skin eruption were recognized in 14 subjects. However, the serious side effect was not recognized.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) A person who has an allergy to cinnamon bark 2) A person with the infectious disease that fever more than or equal to 38 degrees Celsius continues. 3) A person with bronchial asthma and serious respiratory diseases 4) A person who is pregnant or may be pregnant 5) Moreover, a person who is evaluated by doctor as an unsuitable for this study
研究者
相似试验
已完成
2 期
Therapeutic application of sodium pyruvate to patients of severe mitochondrial disordersmitochondrial disordersJPRN-UMIN000008341Department of Pediatrics, Hiroshima University Hospital20
终止
1 期
Study to evaluate the safety, tolerability, and efficacy of enoxaparin for inhalation alone and in combination with N-acetylcysteine in healthy volunteers and hospitalised COVID-19 patientsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)COVID-19Respiratory - Other respiratory disorders / diseasesInfection - Other infectious diseasesACTRN12621000704897Atossa Genetics Aus Pty Ltd41
已完成
1 期
A Four-Part Study to Determine the Safety, Tolerability and Pharmacokinetics of the Oxette (Registered Trademark) Nicotine Inhaler, Including a Comparison with the Nicorette (Registered Trademark) InhalerACTRN12612000088842Kind Consumer Limited60
招募中
1 期
Study of B/F/TAF in Participants Switching from CAB + RPV to B/F/TAF for HIV-1 Infection.HIV-1 infectionMedDRA version: 20.1Level: LLTClassification code: 10068341Term: HIV-1 infection Class: 10021881CTIS2023-506660-13-00Gilead Sciences Inc.35
已完成
4 期
A Post Marketing study of VELSEAL to control the bleeding from severely bleeding wounds due to accidents, trauma cases and deep arterial wounds.CTRI/2018/03/012373Datt Mediproducts Pvt Ltd101